On the roles of polyvalent binding in immune recognition: Perspectives in the nanoscience of immunology and the immune response to nanomedicines

Advanced Drug Delivery Reviews

Volumn 64, Issue 15, 2012, Pages 1759-1781

  Vorup Jensen, Thomas ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

Adhesion molecules; Avidity; Immunoglobulins; Integrins; Mannan binding lectin; Nanotoxicology; Polyvalent binding

Indexed keywords

ADHESION MOLECULES; AVIDITY; IMMUNOGLOBULINS; INTEGRINS; MANNAN-BINDING LECTINS; NANOTOXICOLOGY; POLYVALENT BINDING;

ADHESION; CELL MEMBRANES; CYTOLOGY; MOLECULES; PATTERN RECOGNITION; THERMODYNAMICS;

IMMUNOLOGY;

CD18 ANTIGEN; CD2 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; NANOPARTICLE;

ADAPTIVE IMMUNITY; ANTIGEN BINDING; ANTIGEN RECOGNITION; BINDING AFFINITY; BINDING SITE; CELL MEMBRANE; CHEMICAL STRUCTURE; CONFORMATIONAL TRANSITION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INNATE IMMUNITY; LEUKOCYTE ADHERENCE; LEUKOCYTE FUNCTION; LIGAND BINDING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR WEIGHT; NANOMEDICINE; NANOTOXICOLOGY; PATTERN RECOGNITION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW;

ANIMALS; CELL ADHESION MOLECULES; CELL MEMBRANE; HUMANS; IMMUNE SYSTEM; LEUKOCYTES; NANOMEDICINE; NANOPARTICLES; RECEPTORS, CELL SURFACE; THERMODYNAMICS;

EID: 84869201214     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.06.003     Document Type: Review

References (256)

1. Mammen M., Choi S.K., Whitesides G.M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Ed. 1998, 37:2755-2794.
2. Weil R. Studies in Anaphylaxis: XV. Equilibrium in Precipitation Reactions. Equilibrium in Combination. J. Immunol. 1916, 1:19-34.
3. Karush F. Multivalent binding and functional affinity. Contemp. Top. Mol. Immunol. 1976, 5:217-228.
4. Burnet F.M., Keogh E.V., Lusk D. The Immunological reactions of filterable viruses. Aust. J. Exp. Biol. Med. Sci. 1937, 15:226-368.
5. Langmuir I. The constitution and fundamental properties of solids and liquids. Part I. Solids. J. Am. Chem. Soc. 1916, 38:2221-2295.
6. Crothers D.M., Metzger H. The influence of polyvalency on the binding properties of antibodies. Immunochemistry 1972, 9:341-357.
7. Kitov P.I., Bundle D.R. On the nature of the multivalency effect: a thermodynamic model. J. Am. Chem. Soc. 2003, 125:16271-16284.
8. Eisen H.N., Karush F. The interaction of purified antibody with homologous hapten; antibody valence and binding constant. J. Am. Chem. Soc. 1949, 71:363.
9. Porter R.R. The hydrolysis of rabbit y-globulin and antibodies with crystalline papain. Biochem. J. 1959, 73:119-126.
10. Fleischman J.B., Porter R.R., Press E.M. The Arrangement of the Peptide Chains in Gamma-Globulin. Biochem. J. 1963, 88:220-228.
11. Hornick C.L., Karuch F. Antibody affinity. 3. The role of multivalance. Immunochemistry 1972, 9:325-340.
12. Jencks W.P. Binding energy, specificity, and enzymic catalysis - the circe effect. Adv in Enzymol 1975, John Wiley and Sons, New York. A. Meister (Ed.).
13. Bell G.I. Models for the specific adhesion of cells to cells. Science 1978, 200:618-627.
14. Klein J.S., Bjorkman P.J. Few and far between: how HIV may be evading antibody avidity. PLoS Pathog. 2010, 6:e1000908.
15. Feinstein A., Munn E.A. Conformation of the free and antigen-bound IgM antibody molecules. Nature 1969, 224:1307-1309.
16. Roux K.H. Immunoglobulin structure and function as revealed by electron microscopy. Int. Arch. Allergy Immunol. 1999, 120:85-99.
17. Jencks W.P. On the attribution and additivity of binding energies. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:4046-4050.
18. Rappaport H.P. Evaluation of group contributions to ligand binding. J. Theor. Biol. 1979, 79:157-165.
19. Jayaraman N. Multivalent ligand presentation as a central concept to study intricate carbohydrate-protein interactions. Chem. Soc. Rev. 2009, 38:3463-3483.
20. van der Merwe P.A., Davis S.J. Molecular interactions mediating T cell antigen recognition. Annu. Rev. Immunol. 2003, 21:659-684.
21. Irvine D.J., Purbhoo M.A., Krogsgaard M., Davis M.M. Direct observation of ligand recognition by T cells. Nature 2002, 419:845-849.
22. Munn L.L., Dupin M.M. Blood cell interactions and segregation in flow. Ann. Biomed. Eng. 2008, 36:534-544.
23. Springer T.A. Adhesion receptors of the immune system. Nature 1990, 346:425-434.
24. Hanna S., Etzioni A. Leukocyte adhesion deficiencies. Ann. N. Y. Acad. Sci. 2012, 1250:50-55.
25. Strober B.E., Menon K. Alefacept for the treatment of psoriasis and other dermatologic diseases. Dermatol. Ther. 2007, 20:270-276.
26. Talamonti M., Spallone G., Di Stefani A., Costanzo A., Chimenti S. Efalizumab. Expert Opin. Drug Saf. 2011, 10:239-251.
27. Iaffaldano P., Lucchese G., Trojano M. Treating multiple sclerosis with natalizumab. Expert Rev. Neurother. 2011, 11:1683-1692.
28. Karush F. Affinity and the immune response. Ann. N. Y. Acad. Sci. 1970, 169:56-64.
29. Janeway C.A. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 1989, 54(Pt 1):1-13.
30. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
31. Beutler B. The Toll-like receptors: analysis by forward genetic methods. Immunogenetics 2005, 57:385-392.
32. Park B.S., Song D.H., Kim H.M., Choi B.S., Lee H., Lee J.O. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009, 458:1191-1195.
33. Yoon S.I., Kurnasov O., Natarajan V., Hong M., Gudkov A.V., Osterman A.L., Wilson I.A. Structural basis of TLR5-flagellin recognition and signaling. Science 2012, 335:859-864.
34. Smith K.D., Andersen-Nissen E., Hayashi F., Strobe K., Bergman M.A., Barrett S.L., Cookson B.T., Aderem A. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat. Immunol. 2003, 4:1247-1253.
35. Andersen-Nissen E., Smith K.D., Strobe K.L., Barrett S.L., Cookson B.T., Logan S.M., Aderem A. Evasion of Toll-like receptor 5 by flagellated bacteria. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9247-9252.
36. Matzinger P. The danger model: a renewed sense of self. Science 2002, 296:301-305.
37. Sheriff S., Chang C.Y., Ezekowitz R.A. Human mannose-binding protein carbohydrate recognition domain trimerizes through a triple alpha-helical coiled-coil. Nat. Struct. Biol. 1994, 1:789-794.
38. Weis W.I., Drickamer K. Trimeric structure of a C-type mannose-binding protein. Structure 1994, 2:1227-1240.
39. Hoffmann J.A., Kafatos F.C., Janeway C.A., Ezekowitz R.A. Phylogenetic perspectives in innate immunity. Science 1999, 284:1313-1318.
40. Krarup A., Sorensen U.B., Matsushita M., Jensenius J.C., Thiel S. Effect of capsulation of opportunistic pathogenic bacteria on binding of the pattern recognition molecules mannan-binding lectin, L-ficolin, and H-ficolin. Infect. Immun. 2005, 73:1052-1060.
41. Bentley S.D., Aanensen D.M., Mavroidi A., Saunders D., Rabbinowitsch E., Collins M., Donohoe K., Harris D., Murphy L., Quail M.A., Samuel G., Skovsted I.C., Kaltoft M.S., Barrell B., Reeves P.R., Parkhill J., Spratt B.G. Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. PLoS Genet. 2006, 2:e31.
42. Holmskov U., Thiel S., Jensenius J.C. Collections and ficolins: humoral lectins of the innate immune defense. Annu. Rev. Immunol. 2003, 21:547-578.
43. Burnet F.M., Mc C.J. Inhibitory and activating action of normal ferret sera against an influenza virus strain. Aust. J. Exp. Biol. Med. Sci. 1946, 24:277-282.
44. Anders E.M., Hartley C.A., Jackson D.C. Bovine and mouse serum beta inhibitors of influenza A viruses are mannose-binding lectins. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:4485-4489.
45. Weis W.I., Brunger A.T., Skehel J.J., Wiley D.C. Refinement of the influenza virus hemagglutinin by simulated annealing. J. Mol. Biol. 1990, 212:737-761.
46. Tate M.D., Brooks A.G., Reading P.C. Specific sites of N-linked glycosylation on the hemagglutinin of H1N1 subtype influenza A virus determine sensitivity to inhibitors of the innate immune system and virulence in mice. J. Immunol. 2011, 187:1884-1894.
47. Selvaraj P., Plunkett M.L., Dustin M., Sanders M.E., Shaw S., Springer T.A. The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3. Nature 1987, 326:400-403.
48. Davis S.J., Davies E.A., Tucknott M.G., Jones E.Y., van der Merwe P.A. The role of charged residues mediating low affinity protein-protein recognition at the cell surface by CD2. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:5490-5494.
49. Wang J.H., Smolyar A., Tan K., Liu J.H., Kim M., Sun Z.Y., Wagner G., Reinherz E.L. Structure of a heterophilic adhesion complex between the human CD2 and CD58 (LFA-3) counterreceptors. Cell 1999, 97:791-803.
50. Lo Conte L., Chothia C., Janin J. The atomic structure of protein-protein recognition sites. J. Mol. Biol. 1999, 285:2177-2198.
51. van der Merwe P.A., Barclay A.N., Mason D.W., Davies E.A., Morgan B.P., Tone M., Krishnam A.K., Ianelli C., Davis S.J. Human cell-adhesion molecule CD2 binds CD58 (LFA-3) with a very low affinity and an extremely fast dissociation rate but does not bind CD48 or CD59. Biochemistry 1994, 33:10149-10160.
52. Dustin M.L., Golan D.E., Zhu D.M., Miller J.M., Meier W., Davies E.A., van der Merwe P.A. Low affinity interaction of human or rat T cell adhesion molecule CD2 with its ligand aligns adhering membranes to achieve high physiological affinity. J. Biol. Chem. 1997, 272:30889-30898.
53. Zhu D.M., Dustin M.L., Cairo C.W., Golan D.E. Analysis of two-dimensional dissociation constant of laterally mobile cell adhesion molecules. Biophys. J. 2007, 92:1022-1034.
54. Zhu D.M., Dustin M.L., Cairo C.W., Thatte H.S., Golan D.E. Mechanisms of Cellular Avidity Regulation in CD2-CD58-Mediated T Cell Adhesion. ACS Chem. Biol. 2006, 1:649-658.
55. Chan P.Y., Lawrence M.B., Dustin M.L., Ferguson L.M., Golan D.E., Springer T.A. Influence of receptor lateral mobility on adhesion strengthening between membranes containing LFA-3 and CD2. J. Cell Biol. 1991, 115:245-255.
56. Hogg N., Patzak I., Willenbrock F. The insider's guide to leukocyte integrin signalling and function. Nat. Rev. Immunol. 2011, 11:416-426.
57. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-687.
58. Edwards Y.J., Perkins S.J. The protein fold of the von Willebrand factor type A domain is predicted to be similar to the open twisted beta-sheet flanked by alpha-helices found in human ras-p21. FEBS Lett. 1995, 358:283-286.
59. Shimaoka M., Takagi J., Springer T.A. Conformational regulation of integrin structure and function. Annu. Rev. Biophys. Biomol. Struct. 2002, 31:485-516.
60. Rossman M.G., Liljas A., Bränden C.-I., Banaszak L.J. Evolutionary and structural relationships among dehydrogenases 1975, 61-102. The Enzymes Academic Press, New York. P.D. Boyer (Ed.).
61. Springer T.A. Folding of the N-terminal, ligand-binding region of integrin alpha-subunits into a beta-propeller domain. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:65-72.
62. Xie C., Zhu J., Chen X., Mi L., Nishida N., Springer T.A. Structure of an integrin with an alphaI domain, complement receptor type 4. EMBO J. 2010, 29:666-679.
63. Huang C., Zang Q., Takagi J., Springer T.A. Structural and functional studies with antibodies to the integrin beta 2 subunit. A model for the I-like domain. J. Biol. Chem. 2000, 275:21514-21524.
64. Plow E.F., Haas T.A., Zhang L., Loftus J., Smith J.W. Ligand binding to integrins. J. Biol. Chem. 2000, 275:21785-21788.
65. Pierschbacher M.D., Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984, 309:30-33.
66. Ruoslahti E. The RGD story: a personal account. Matrix Biol. 2003, 22:459-465.
67. Ruoslahti E. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 1996, 12:697-715.
68. Emsley J., Knight C.G., Farndale R.W., Barnes M.J., Liddington R.C. Structural basis of collagen recognition by integrin alpha2beta1. Cell 2000, 101:47-56.
69. Shimaoka M., Xiao T., Liu J.H., Yang Y., Dong Y., Jun C.D., McCormack A., Zhang R., Joachimiak A., Takagi J., Wang J.H., Springer T.A. Structures of the alpha L I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell 2003, 112:99-111.
70. van der Merwe P.A., Barclay A.N. Transient intercellular adhesion: the importance of weak protein-protein interactions. Trends Biochem. Sci. 1994, 19:354-358.
71. Stapulionis R., Oliveira C.L., Gjelstrup M.C., Pedersen J.S., Hokland M.E., Hoffmann S.V., Poulsen K., Jacobsen C., Vorup-Jensen T. Structural insight into the function of myelin basic protein as a ligand for integrin alpha M beta 2. J. Immunol. 2008, 180:3946-3956.
72. Arnon R., Aharoni R. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(Suppl. 2):14593-14598.
73. Vorup-Jensen T., Carman C.V., Shimaoka M., Schuck P., Svitel J., Springer T.A. Exposure of acidic residues as a danger signal for recognition of fibrinogen and other macromolecules by integrin alphaXbeta2. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:1614-1619.
74. Vorup-Jensen T. Surface plasmon resonance biosensing in studies of the binding between beta integrin I domains and their ligands. Methods Mol. Biol. 2012, 757:55-71.
75. Harris E.S., McIntyre T.M., Prescott S.M., Zimmerman G.A. The leukocyte integrins. J. Biol. Chem. 2000, 275:23409-23412.
76. Vorup-Jensen T., Ostermeier C., Shimaoka M., Hommel U., Springer T.A. Structure and allosteric regulation of the alpha X beta 2 integrin I domain. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:1873-1878.
77. Chen X., Yu Y., Mi L.Z., Walz T., Springer T.A. Molecular basis for complement recognition by integrin alphaXbeta2. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:4586-4591.
78. Schuck P., Zhao H. The role of mass transport limitation and surface heterogeneity in the biophysical characterization of macromolecular binding processes by SPR biosensing. Methods Mol. Biol. 2010, 627:15-54.
79. Gorshkova J., Svitel F., Razjouyan P. Schuck, Bayesian analysis of heterogeneity in the distribution of binding properties of immobilized surface sites. Langmuir 2008, 24:11577-11586.
80. Svitel J., Balbo A., Mariuzza R.A., Gonzales N.R., Schuck P. Combined affinity and rate constant distributions of ligand populations from experimental surface binding kinetics and equilibria. Biophys. J. 2003, 84:4062-4077.
81. Lerch P.G., Rickli E.E., Lergier W., Gillessen D. Localization of individual lysine-binding regions in human plasminogen and investigations on their complex-forming properties. Eur. J. Biochem. 1980, 107:7-13.
82. Michaelis E.K., Michaelis M.L., Stormann T.M., Chittenden W.L., Grubbs R.D. Purification and molecular characterization of the brain synaptic membrane glutamate-binding protein. J. Neurochem. 1983, 40:1742-1753.
83. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994, 76:301-314.
84. Vorup-Jensen T., Chi L., Gjelstrup L.C., Jensen U.B., Jewett C.A., Xie C., Shimaoka M., Linhardt R.J., Springer T.A. Binding between the integrin alphaXbeta2 (CD11c/CD18) and heparin. J. Biol. Chem. 2007, 282:30869-30877.
85. Schack L., Stapulionis R., Christensen B., Kofod-Olsen E., Skov Sorensen U.B., Vorup-Jensen T., Sorensen E.S., Hollsberg P. Osteopontin enhances phagocytosis through a novel osteopontin receptor, the alphaXbeta2 integrin. J. Immunol. 2009, 182:6943-6950.
86. Lee J.H., Choi J., Nham S.U. Critical residues of alphaX I-domain recognizing fibrinogen central domain. Biochem. Biophys. Res. Commun. 2007, 355:1058-1063.
87. Diamond M.S., Alon R., Parkos C.A., Quinn M.T., Springer T.A. Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1). J. Cell Biol. 1995, 130:1473-1482.
88. Laremore T.N., Zhang F., Dordick J.S., Liu J., Linhardt R.J. Recent progress and applications in glycosaminoglycan and heparin research. Curr. Opin. Chem. Biol. 2009, 13:633-640.
89. Gandhi N.S., Mancera R.L. Free energy calculations of glycosaminoglycan-protein interactions. Glycobiology 2009, 19:1103-1115.
90. Sankhala R.S., Damai R.S., Anbazhagan V., Kumar C.S., Bulusu G., Swamy M.J. Biophysical investigations on the interaction of the major bovine seminal plasma protein, PDC-109, with heparin. J. Phys. Chem. B 2011, 115:12954-12962.
91. Carlson T.H., Babcock T., Atencio A.C., Levinson C., Mora H.R. Behavior of antithrombin III isoforms on immobilized heparins. Evidence that the isoforms bind to different numbers of low-affinity heparin sites. J. Biol. Chem. 1988, 263:2187-2194.
92. Davis G.E. The Mac-1 and p150,95 beta 2 integrins bind denatured proteins to mediate leukocyte cell-substrate adhesion. Exp. Cell Res. 1992, 200:242-252.
93. Yalamanchili P., Lu C., Oxvig C., Springer T.A. Folding and function of I domain-deleted Mac-1 and lymphocyte function-associated antigen-1. J. Biol. Chem. 2000, 275:21877-21882.
94. Solovjov D.A., Pluskota E., Plow E.F. Distinct roles for the alpha and beta subunits in the functions of integrin alphaMbeta2. J. Biol. Chem. 2005, 280:1336-1345.
95. Tang M.L., Kong L.S., Law S.K., Tan S.M. Down-regulation of integrin alpha M beta 2 ligand-binding function by the urokinase-type plasminogen activator receptor. Biochem. Biophys. Res. Commun. 2006, 348:1184-1193.
96. Davis G.E. Affinity of integrins for damaged extracellular matrix: alpha v beta 3 binds to denatured collagen type I through RGD sites. Biochem. Biophys. Res. Commun. 1992, 182:1025-1031.
97. Davis G.E., Thomas J.S., Madden S. The alpha4beta1 integrin can mediate leukocyte adhesion to casein and denatured protein substrates. J. Leukoc. Biol. 1997, 62:318-328.
98. Suzuki K., Namiki H. Proteolysis of fibrinogen deposits enables hydrogen peroxide-stimulated polymorphonuclear leukocytes to spread in an acidified environment. Eur. J. Pharmacol. 2009, 609:140-147.
99. Lee J.O., Rieu P., Arnaout M.A., Liddington R. Crystal structure of the A domain from the alpha subunit of integrin CR3 (CD11b/CD18). Cell 1995, 80:631-638.
100. Shimaoka M., Shifman J.M., Jing H., Takagi J., Mayo S.L., Springer T.A. Computational design of an integrin I domain stabilized in the open high affinity conformation. Nat. Struct. Biol. 2000, 7:674-678.
101. Shimaoka M., Lu C., Salas A., Xiao T., Takagi J., Springer T.A. Stabilizing the integrin alpha M inserted domain in alternative conformations with a range of engineered disulfide bonds. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:16737-16741.
102. Lu C., Shimaoka M., Ferzly M., Oxvig C., Takagi J., Springer T.A. An isolated, surface-expressed I domain of the integrin alphaLbeta2 is sufficient for strong adhesive function when locked in the open conformation with a disulfide bond. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:2387-2392.
103. Shimaoka M., Lu C., Palframan R.T., von Andrian U.H., McCormack A., Takagi J., Springer T.A. Reversibly locking a protein fold in an active conformation with a disulfide bond: integrin alphaL I domains with high affinity and antagonist activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:6009-6014.
104. Astrof N.S., Salas A., Shimaoka M., Chen J., Springer T.A. Importance of force linkage in mechanochemistry of adhesion receptors. Biochemistry 2006, 45:15020-15028.
105. Vorup-Jensen T., Waldron T.T., Astrof N., Shimaoka M., Springer T.A. The connection between metal ion affinity and ligand affinity in integrin I domains. Biochim. Biophys. Acta 2007, 1774:1148-1155.
106. Jin M., Song G., Carman C.V., Kim Y.S., Astrof N.S., Shimaoka M., Wittrup D.K., Springer T.A. Directed evolution to probe protein allostery and integrin I domains of 200,000-fold higher affinity. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5758-5763.
107. Xiong J.P., Li R., Essafi M., Stehle T., Arnaout M.A. An isoleucine-based allosteric switch controls affinity and shape shifting in integrin CD11b A-domain. J. Biol. Chem. 2000, 275:38762-38767.
108. Luo B.H., Carman C.V., Springer T.A. Structural basis of integrin regulation and signaling. Annu. Rev. Immunol. 2007, 25:619-647.
109. Takagi J., Petre B.M., Walz T., Springer T.A. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell 2002, 110:599-511.
110. Takagi J., Strokovich K., Springer T.A., Walz T. Structure of integrin alpha5beta1 in complex with fibronectin. EMBO J. 2003, 22:4607-4615.
111. Schurpf T., Springer T.A. Regulation of integrin affinity on cell surfaces. EMBO J. 2011, 30:4712-4727.
112. Yang W., Shimaoka M., Salas A., Takagi J., Springer T.A. Intersubunit signal transmission in integrins by a receptor-like interaction with a pull spring. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:2906-2911.
113. Yang W., Shimaoka M., Chen J., Springer T.A. Activation of integrin beta-subunit I-like domains by one-turn C-terminal alpha-helix deletions. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:2333-2338.
114. Lee J.O., Bankston L.A., Arnaout M.A., Liddington R.C. Two conformations of the integrin A-domain (I-domain): a pathway for activation?. Structure 1995, 3:1333-1340.
115. Baldwin E.T., Sarver R.W., Bryant G.L., Curry K.A., Fairbanks M.B., Finzel B.C., Garlick R.L., Heinrikson R.L., Horton N.C., Kelley L.L., Mildner A.M., Moon J.B., Mott J.E., Mutchler V.T., Tomich C.S., Watenpaugh K.D., Wiley V.H. Cation binding to the integrin CD11b I domain and activation model assessment. Structure 1998, 6:923-935.
116. Allgrove J. Physiology of calcium, phosphate and magnesium. Endocr. Dev. 2009, 16:8-31.
117. Dudev T., Lim C. Principles governing Mg, Ca, and Zn binding and selectivity in proteins. Chem. Rev. 2003, 103:773-788.
118. San Sebastian E., Mercero J.M., Stote R.H., Dejaegere A., Cossio F.P., Lopez X. On the affinity regulation of the metal-ion-dependent adhesion sites in integrins. J. Am. Chem. Soc. 2006, 128:3554-3563.
119. Bazzoni G., Hemler M.E. Are changes in integrin affinity and conformation overemphasized?. Trends Biochem. Sci. 1998, 23:30-34.
120. Carman C.V., Springer T.A. Integrin avidity regulation: are changes in affinity and conformation underemphasized?. Curr. Opin. Cell Biol. 2003, 15:547-556.
121. Kendall T., Mukai L., Jannuzi A.L., Bunch T.A. Identification of integrin beta subunit mutations that alter affinity for extracellular matrix ligand. J. Biol. Chem. 2011, 286:30981-30993.
122. Park E.J., Peixoto A., Imai Y., Goodarzi A., Cheng G., Carman C.V., von Andrian U.H., Shimaoka M. Distinct roles for LFA-1 affinity regulation during T-cell adhesion, diapedesis, and interstitial migration in lymph nodes. Blood 2010, 115:1572-1581.
123. Park E.J., Mora J.R., Carman C.V., Chen J., Sasaki Y., Cheng G., von Andrian U.H., Shimaoka M. Aberrant activation of integrin alpha4beta7 suppresses lymphocyte migration to the gut. J. Clin. Invest. 2007, 117:2526-2538.
124. van Zanten T.S., Cambi A., Koopman M., Joosten B., Figdor C.G., Garcia-Parajo M.F. Hotspots of GPI-anchored proteins and integrin nanoclusters function as nucleation sites for cell adhesion. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:18557-18562.
125. Diez-Ahedo R., Normanno D., Esteban O., Bakker G.J., Figdor C.G., Cambi A., Garcia-Parajo M.F. Dynamic re-organization of individual adhesion nanoclusters in living cells by ligand-patterned surfaces. Small 2009, 5:1258-1263.
126. Bakker G.J., Eich C., Torreno-Pina J.A., Diez-Ahedo R., Perez-Samper G., van Zanten T.S., Figdor C.G., Cambi A., Garcia-Parajo M.F. Lateral mobility of individual integrin nanoclusters orchestrates the onset for leukocyte adhesion. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:4869-4874.
127. Cambi A., Joosten B., Koopman M., de Lange F., Beeren I., Torensma R., Fransen J.A., Garcia-Parajo M., van Leeuwen F.N., Figdor C.G. Organization of the integrin LFA-1 in nanoclusters regulates its activity. Mol. Biol. Cell 2006, 17:4270-4281.
128. van Zanten T.S., Cambi A., Garcia-Parajo M.F. A nanometer scale optical view on the compartmentalization of cell membranes. Biochim. Biophys. Acta 2010, 1798:777-787.
129. Vararattanavech A., Lin X., Torres J., Tan S.M. Disruption of the integrin alphaLbeta2 transmembrane domain interface by beta2 Thr-686 mutation activates alphaLbeta2 and promotes micro-clustering of the alphaL subunits. J. Biol. Chem. 2009, 284:3239-3249.
130. Kim M., Carman C.V., Yang W., Salas A., Springer T.A. The primacy of affinity over clustering in regulation of adhesiveness of the integrin {alpha}L{beta}2. J. Cell Biol. 2004, 167:1241-1253.
131. Miller J., Knorr R., Ferrone M., Houdei R., Carron C.P., Dustin M.L. Intercellular adhesion molecule-1 dimerization and its consequences for adhesion mediated by lymphocyte function associated-1. J. Exp. Med. 1995, 182:1231-1241.
132. Reilly P.L., Woska J.R., Jeanfavre D.D., McNally E., Rothlein R., Bormann B.J. The native structure of intercellular adhesion molecule-1 (ICAM-1) is a dimer. Correlation with binding to LFA-1. J. Immunol. 1995, 155:529-532.
133. Oh H.M., Kwon M.S., Kim H.J., Jeon B.H., Kim H.R., Choi H.O., Na B.R., Eom S.H., Song N.W., Jun C.D. Intermediate monomer-dimer equilibrium structure of native ICAM-1: implication for enhanced cell adhesion. Exp. Cell Res. 2011, 317:163-172.
134. Collins A.V., Brodie D.W., Gilbert R.J., Iaboni A., Manso-Sancho R., Walse B., Stuart D.I., van der Merwe P.A., Davis S.J. The interaction properties of costimulatory molecules revisited. Immunity 2002, 17:201-210.
135. Jansson A., Barnes E., Klenerman P., Harlen M., Sorensen P., Davis S.J., Nilsson P. A theoretical framework for quantitative analysis of the molecular basis of costimulation. J. Immunol. 2005, 175:1575-1585.
136. Davis S.J., van der Merwe P.A. The kinetic-segregation model: TCR triggering and beyond. Nat. Immunol. 2006, 7:803-809.
137. Dam T.K., Brewer C.F. Lectins as pattern recognition molecules: the effects of epitope density in innate immunity. Glycobiology 2010, 20:270-279.
138. Jensen P.H., Weilguny D., Matthiesen F., McGuire K.A., Shi L., Hojrup P. Characterization of the oligomer structure of recombinant human mannan-binding lectin. J. Biol. Chem. 2005, 280:11043-11051.
139. Jensenius H., Klein D.C., van Hecke M., Oosterkamp T.H., Schmidt T., Jensenius J.C. Mannan-binding lectin: structure, oligomerization, and flexibility studied by atomic force microscopy. J. Mol. Biol. 2009, 391:246-259.
140. Teillet F., Dublet B., Andrieu J.P., Gaboriaud C., Arlaud G.J., Thielens N.M. The two major oligomeric forms of human mannan-binding lectin: chemical characterization, carbohydrate-binding properties, and interaction with MBL-associated serine proteases. J. Immunol. 2005, 174:2870-2877.
141. Gjelstrup L.C., Kaspersen J.D., Behrens M.A., Pedersen J.S., Thiel S., Kingshott P., Oliveira C.L., Thielens N.M., Vorup-Jensen T. The role of nanometer-scaled ligand patterns in polyvalent binding by large mannan-binding lectin oligomers. J. Immunol. 2012, 188:1292-1306.
142. Arnold J.N., Wormald M.R., Suter D.M., Radcliffe C.M., Harvey D.J., Dwek R.A., Rudd P.M., Sim R.B. Human serum IgM glycosylation: identification of glycoforms that can bind to mannan-binding lectin. J. Biol. Chem. 2005, 280:29080-29087.
143. Zhang M., Takahashi K., Alicot E.M., Vorup-Jensen T., Kessler B., Thiel S., Jensenius J.C., Ezekowitz R.A., Moore F.D., Carroll M.C. Activation of the lectin pathway by natural IgM in a model of ischemia/reperfusion injury. J. Immunol. 2006, 177:4727-4734.
144. Perkins S.J., Nealis A.S., Sutton B.J., Feinstein A. Solution structure of human and mouse immunoglobulin M by synchrotron X-ray scattering and molecular graphics modelling. A possible mechanism for complement activation. J. Mol. Biol. 1991, 221:1345-1366.
145. Czajkowsky D.M., Shao Z. The human IgM pentamer is a mushroom-shaped molecule with a flexural bias. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14960-14965.
146. Gros P., Milder F.J., Janssen B.J. Complement driven by conformational changes. Nat. Rev. Immunol. 2008, 8:48-58.
147. Springer T.A. Biology and physics of von Willebrand factor concatamers. J. Thromb. Haemost. 2011, 9(Suppl. 1):130-143.
148. Pedersen M.B., Zhou X., Larsen E.K., Sorensen U.S., Kjems J., Nygaard J.V., Nyengaard J.R., Meyer R.L., Boesen T., Vorup-Jensen T. Curvature of synthetic and natural surfaces is an important target feature in classical pathway complement activation. J. Immunol. 2010, 184:1931-1945.
149. Vorup-Jensen T., Boesen T. Protein ultrastructure and the nanoscience of complement activation. Adv. Drug Deliv. Rev. 2011, 63:1008-1019.
150. Vorup-Jensen T. Wrong resemblance? Role of the immune system in biocompatibility of nanostructured materials. Handbook of harnessing biomaterials in nanomedicine 2012, 283-301. Pan Stanford Publishing, Singapore. D. Peer (Ed.).
151. Antonny B. Mechanisms of membrane curvature sensing. Annu. Rev. Biochem. 2011, 80:101-123.
152. Lundmark R., Carlsson S.R. Driving membrane curvature in clathrin-dependent and clathrin-independent endocytosis. Semin. Cell Dev. Biol. 2010, 21:363-370.
153. Dong M., Xu S., Oliveira C.L., Pedersen J.S., Thiel S., Besenbacher F., Vorup-Jensen T. Conformational changes in mannan-binding lectin bound to ligand surfaces. J. Immunol. 2007, 178:3016-3022.
154. Gingras A.R., Girija U.V., Keeble A.H., Panchal R., Mitchell D.A., Moody P.C., Wallis R. Structural basis of mannan-binding lectin recognition by its associated serine protease MASP-1: implications for complement activation. Structure 2011, 19:1635-1643.
155. Wang J., Springer T.A. Structural specializations of immunoglobulin superfamily members for adhesion to integrins and viruses. Immunol. Rev. 1998, 163:197-215.
156. Rothlein R., Dustin M.L., Marlin S.D., Springer T.A. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J. Immunol. 1986, 137:1270-1274.
157. Littler A.J., Buckley C.D., Wordsworth P., Collins I., Martinson J., Simmons D.L. A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis. Br. J. Rheumatol. 1997, 36:164-169.
158. Seth R., Raymond F.D., Makgoba M.W. Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune disorders. Lancet 1991, 338:83-84.
159. Shi Q., Benderdour M., Lavigne P., Ranger P., Fernandes J.C. Evidence for two distinct pathways in TNFalpha-induced membrane and soluble forms of ICAM-1 in human osteoblast-like cells isolated from osteoarthritic patients. Osteoarthritis Cartilage 2007, 15:300-308.
160. Trojano M., Avolio C., Liuzzi G.M., Ruggieri M., Defazio G., Liguori M., Santacroce M.P., Paolicelli D., Giuliani F., Riccio P., Livrea P. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 1999, 53:1402-1408.
161. Fiore E., Fusco C., Romero P., Stamenkovic I. Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene 2002, 21:5213-5223.
162. Rothlein R., Mainolfi E.A., Czajkowski M., Marlin S.D. A form of circulating ICAM-1 in human serum. J. Immunol. 1991, 147:3788-3793.
163. Staunton D.E., Dustin M.L., Erickson H.P., Springer T.A. The arrangement of the immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and rhinovirus. Cell 1990, 61:243-254.
164. Diamond M.S., Staunton D.E., Marlin S.D., Springer T.A. Binding of the integrin Mac-1 (CD11b/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation. Cell 1991, 65:961-971.
165. Jun C.D., Shimaoka M., Carman C.V., Takagi J., Springer T.A. Dimerization and the effectiveness of ICAM-1 in mediating LFA-1-dependent adhesion. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:6830-6835.
166. Jun C.D., Carman C.V., Redick S.D., Shimaoka M., Erickson H.P., Springer T.A. Ultrastructure and function of dimeric, soluble intercellular adhesion molecule-1 (ICAM-1). J. Biol. Chem. 2001, 276:29019-29027.
167. Casasnovas J.M., Stehle T., Liu J.H., Wang J.H., Springer T.A. A dimeric crystal structure for the N-terminal two domains of intercellular adhesion molecule-1. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:4134-4139.
168. Yang Y., Jun C.D., Liu J.H., Zhang R., Joachimiak A., Springer T.A., Wang J.H. Structural basis for dimerization of ICAM-1 on the cell surface. Mol. Cell 2004, 14:269-276.
169. Mitchell J.B., Thornton J.M., Singh J., Price S.L. Towards an understanding of the arginine-aspartate interaction. J. Mol. Biol. 1992, 226:251-262.
170. Chen X., Kim T.D., Carman C.V., Mi L.Z., Song G., Springer T.A. Structural plasticity in Ig superfamily domain 4 of ICAM-1 mediates cell surface dimerization. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:15358-15363.
171. Evans B.J., McDowall A., Taylor P.C., Hogg N., Haskard D.O., Landis R.C. Shedding of lymphocyte function-associated antigen-1 (LFA-1) in a human inflammatory response. Blood 2006, 107:3593-3599.
172. Vaisar T., Kassim S.Y., Gomez I.G., Green P.S., Hargarten S., Gough P.J., Parks W.C., Wilson C.L., Raines E.W., Heinecke J.W. MMP-9 sheds the beta2 integrin subunit (CD18) from macrophages. Mol. Cell. Proteomics 2009, 8:1044-1060.
173. Stefanidakis M., Karjalainen K., Jaalouk D.E., Gahmberg C.G., O'Brien S., Pasqualini R., Arap W., Koivunen E. Role of leukemia cell invadosome in extramedullary infiltration. Blood 2009, 114:3008-3017.
174. Stefanidakis M., Bjorklund M., Ihanus E., Gahmberg C.G., Koivunen E. Identification of a negatively charged peptide motif within the catalytic domain of progelatinases that mediates binding to leukocyte beta 2 integrins. J. Biol. Chem. 2003, 278:34674-34684.
175. Shin H.Y., Simon S.I., Schmid-Schonbein G.W. Fluid shear-induced activation and cleavage of CD18 during pseudopod retraction by human neutrophils. J. Cell. Physiol. 2008, 214:528-536.
176. Zen K., Guo Y.L., Li L.M., Bian Z., Zhang C.Y., Liu Y. Cleavage of the CD11b extracellular domain by the leukocyte serprocidins is critical for neutrophil detachment during chemotaxis. Blood 2011, 117:4885-4894.
177. Gomez I.G., Tang J., Wilson C.L., Yan W., Heinecke J.W., Harlan J.M., Raines E.W. Metalloproteinase-mediated Shedding of Integrin beta2 Promotes Macrophage Efflux from Inflammatory Sites. J. Biol. Chem. 2012, 287:4581-4589.
178. Davis T.L., Rabinovitz I., Futscher B.W., Schnolzer M., Burger F., Liu Y., Kulesz-Martin M., Cress A.E. Identification of a novel structural variant of the alpha 6 integrin. J. Biol. Chem. 2001, 276:26099-26106.
179. Pawar S.C., Demetriou M.C., Nagle R.B., Bowden G.T., Cress A.E. Integrin alpha6 cleavage: a novel modification to modulate cell migration. Exp. Cell Res. 2007, 313:1080-1089.
180. von Bredow D.C., Nagle R.B., Bowden G.T., Cress A.E. Cleavage of beta 4 integrin by matrilysin. Exp. Cell Res. 1997, 236:341-345.
181. Gjelstrup L.C., Boesen T., Kragstrup T.W., Jorgensen A., Klein N.J., Thiel S., Deleuran B.W., Vorup-Jensen T. Shedding of large functionally active CD11/CD18 Integrin complexes from leukocyte membranes during synovial inflammation distinguishes three types of arthritis through differential epitope exposure. J. Immunol. 2010, 185:4154-4168.
182. Szebeni J., Muggia F., Gabizon A., Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv. Drug Deliv. Rev. 2011, 63:1020-1030.
183. Moghimi S.M., Hunter A.C., Andresen T.L. Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective. Annu. Rev. Pharmacol. Toxicol. 2012, 52:481-503.
184. Chertow G.M., Mason P.D., Vaage-Nilsen O., Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol. Dial. Transplant. 2006, 21:378-382.
185. Lu M., Cohen M.H., Rieves D., Pazdur R. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am. J. Hematol. 2010, 85:315-319.
186. Bernd H., De Kerviler E., Gaillard S., Bonnemain B. Safety and tolerability of ultrasmall superparamagnetic iron oxide contrast agent: comprehensive analysis of a clinical development program. Invest. Radiol. 2009, 44:336-342.
187. Marradi M., Garcia I., Penades S. Carbohydrate-based nanoparticles for potential applications in medicine. Prog. Mol. Biol. Transl. Sci. 2011, 104:141-173.
188. Wittenborn T., Nielsen T., Nygaard J.V., Larsen E.K., Thim T., Rydtoft L.M., Vorup-Jensen T., Kjems J., Nielsen N.C., Horsman M.R., Falk E. Ultrahigh-field DCE-MRI of angiogenesis in a novel angiogenesis mouse model. J. Magn. Reson. Imaging 2012, 35:703-710.
189. Paul K.G., Frigo T.B., Groman J.Y., Groman E.V. Synthesis of ultrasmall superparamagnetic iron oxides using reduced polysaccharides. Bioconjug. Chem. 2004, 15:394-401.
190. Karmali P.P., Chao Y., Park J.H., Sailor M.J., Ruoslahti E., Esener S.C., Simberg D. Different effect of hydrogelation on antifouling and circulation properties of dextran-iron oxide nanoparticles. Mol. Pharm. 2012, 9:539-545.
191. Fenoglio I., Fubini B., Ghibaudi E.M., Turci F. Multiple aspects of the interaction of biomacromolecules with inorganic surfaces. Adv. Drug Deliv. Rev. 2011, 63:1186-1209.
192. Simberg D., Park J.H., Karmali P.P., Zhang W.M., Merkulov S., McCrae K., Bhatia S.N., Sailor M., Ruoslahti E. Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. Biomaterials 2009, 30:3926-3933.
193. Pinegin B.V., Kulakov A.V., Makarov E.A., Ledger P.W., Khaitov R.M. The occurrence of natural antibodies to minimal component of bacterial cell wall (N-acetylglucosaminyl-N-acetylmuramyl dipeptide) in sera from healthy humans. Immunol. Lett. 1995, 47:33-37.
194. Foote J.B., Mahmoud T.I., Vale A.M., Kearney J.F. Long-term maintenance of polysaccharide-specific antibodies by IgM-secreting cells. J. Immunol. 2012, 188:57-67.
195. Karmali P.P., Simberg D. Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert Opin. Drug Deliv. 2011, 8:343-357.
196. Feynman R. There's Plenty of Room at the Bottom. Eng. Sci. 1960, 23(23):22-36.
197. Chan H.K., Kwok P.C. Production methods for nanodrug particles using the bottom-up approach. Adv. Drug Deliv. Rev. 2011, 63:406-416.
198. Ruoslahti E., Bhatia S.N., Sailor M.J. Targeting of drugs and nanoparticles to tumors. J. Cell Biol. 2010, 188:759-768.
199. Liu P., Sun J., Huang J., Peng R., Tang J., Ding J. Fabrication of micropatterns of nanoarrays on a polymeric gel surface. Nanoscale 2010, 2:122-127.
200. Harrison S.C. The familiar and the unexpected in structures of icosahedral viruses. Curr. Opin. Struct. Biol. 2001, 11:195-199.
201. Knobler C.M., Gelbart W.M. Physical chemistry of DNA viruses. Annu. Rev. Phys. Chem. 2009, 60:367-383.
202. Lindert S., Silvestry M., Mullen T.M., Nemerow G.R., Stewart P.L. Cryo-electron microscopy structure of an adenovirus-integrin complex indicates conformational changes in both penton base and integrin. J. Virol. 2009, 83:11491-11501.
203. Touhami A., Jericho M.H., Beveridge T.J. Atomic force microscopy of cell growth and division in Staphylococcus aureus. J. Bacteriol. 2004, 186:3286-3295.
204. Puzyn T., Leszczynska D., Leszczynski J. Toward the development of "nano-QSARs": advances and challenges. Small 2009, 5:2494-2509.
205. Borm P.J., Robbins D., Haubold S., Kuhlbusch T., Fissan H., Donaldson K., Schins R., Stone V., Kreyling W., Lademann J., Krutmann J., Warheit D., Oberdorster E. The potential risks of nanomaterials: a review carried out for ECETOC. Part. Fibre Toxicol. 2006, 3:11.
206. Moghimi S.M., Andersen A.J., Ahmadvand D., Wibroe P.P., Andresen T.L., Hunter A.C. Material properties in complement activation. Adv. Drug Deliv. Rev. 2011, 63:1000-1007.
207. Deng Z.J., Liang M., Monteiro M., Toth I., Minchin R.F. Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. Nat. Nanotechnol. 2011, 6:39-44.
208. Goy-Lopez S., Juarez J., Alatorre-Meda M., Casals E., Puntes V.F., Taboada P., Mosquera V. Physico-chemical characteristics of protein-NP bioconjugates: The role of particle curvature and solution conditions on human serum albumin conformation and fibrillogenesis inhibition. Langmuir 2012, 28:9113-9126.
209. Park H., Adsit F.G., Boyington J.C. The 1.5 A crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding. J. Biol. Chem. 2011, 285:40762-40770.
210. Brevig T., Holst B., Ademovic Z., Rozlosnik N., Rohrmann J.H., Larsen N.B., Hansen O.C., Kingshott P. The recognition of adsorbed and denatured proteins of different topographies by beta2 integrins and effects on leukocyte adhesion and activation. Biomaterials 2005, 26:3039-3053.
211. Tang L., Ugarova T.P., Plow E.F., Eaton J.W. Molecular determinants of acute inflammatory responses to biomaterials. J. Clin. Invest. 1996, 97:1329-1334.
212. Hu W.J., Eaton J.W., Ugarova T.P., Tang L. Molecular basis of biomaterial-mediated foreign body reactions. Blood 2001, 98:1231-1238.
213. Barbosa J.N., Madureira P., Barbosa M.A., Aguas A.P. The attraction of Mac-1+ phagocytes during acute inflammation by methyl-coated self-assembled monolayers. Biomaterials 2005, 26:3021-3027.
214. Giavaresi G., Tschon M., Daly J.H., Liggat J.J., Sutherland D.S., Agheli H., Fini M., Torricelli P., Giardino R. In vitro and in vivo response to nanotopographically-modified surfaces of poly(3-hydroxybutyrate-co-3-hydroxyvalerate) and polycaprolactone. J. Biomater. Sci. Polym. Ed. 2006, 17:1405-1423.
215. Ding N., Kunugita N., Ichinose T., Song Y., Yokoyama M., Arashidani K., Yoshida Y. Intratracheal administration of fullerene nanoparticles activates splenic CD11b+ cells. J. Hazard. Mater. 2011, 194:324-330.
216. Azevedo R.B., Valois C.R., Chaves S.B., Silva J.R., Garcia M.P. Leukocyte transepithelial migration in lung induced by DMSA functionalized magnetic nanoparticles. Cell Adh. Migr. 2011, 5:29-33.
217. Feldmann M. Many cytokines are very useful therapeutic targets in disease. J. Clin. Invest. 2008, 118:3533-3536.
218. Simmons D.L. Anti-adhesion therapies. Curr. Opin. Pharmacol. 2005, 5:398-404.
219. Chen X., Wong R., Khalidov I., Wang A.Y., Leelawattanachai J., Wang Y., Jin M.M. Inflamed leukocyte-mimetic nanoparticles for molecular imaging of inflammation. Biomaterials 2011, 32:7651-7661.
220. Kang S., Park T., Chen X., Dickens G., Lee B., Lu K., Rakhilin N., Daniel S., Jin M.M. Tunable physiologic interactions of adhesion molecules for inflamed cell-selective drug delivery. Biomaterials 2011, 32:3487-3498.
221. Park S., Kang S., Veach A.J., Vedvyas Y., Zarnegar R., Kim J.Y., Jin M.M. Self-assembled nanoplatform for targeted delivery of chemotherapy agents via affinity-regulated molecular interactions. Biomaterials 2010, 31:7766-7775.
222. Lowes M.A., Chamian F., Abello M.V., Leonardi C., Dummer W., Papp K., Krueger J.G. Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series. BMC Dermatol. 2007, 7:2.
223. Krissinel E., Henrick K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 2007, 372:774-797.
224. Kortemme T., Kim D.E., Baker D. Computational alanine scanning of protein-protein interfaces. Sci. STKE 2004, 2004:l2.
225. Kortemme T., Baker D. A simple physical model for binding energy hot spots in protein-protein complexes. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:14116-14121.
226. Aranyi P. Kinetics of the hormone-receptor interaction. Competition experiments with slowly equilibrating ligands. Biochim. Biophys. Acta 1980, 628:220-227.
227. Lishko V.K., Novokhatny V.V., Yakubenko V.P., Skomorovska-Prokvolit H.V., Ugarova T.P. Characterization of plasminogen as an adhesive ligand for integrins alphaMbeta2 (Mac-1) and alpha5beta1 (VLA-5). Blood 2004, 104:719-726.
228. Gang J., Choi J., Lee J.H., Nham S.U. Identification of critical residues for plasminogen binding by the alphaX I-domain of the beta2 integrin, alphaXbeta2. Mol. Cells 2007, 24:240-246.
229. Benimetskaya L., Loike J.D., Khaled Z., Loike G., Silverstein S.C., Cao L., El Khoury J., Cai T.Q., Stein C.A. Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein. Nat. Med. 1997, 3:414-420.
230. Wong K.F., Luk J.M., Cheng R.H., Klickstein L.B., Fan S.T. Characterization of two novel LPS-binding sites in leukocyte integrin betaA domain. FASEB J. 2007, 21:3231-3239.
231. Ingalls R.R., Arnaout M.A., Delude R.L., Flaherty S., Savedra R., Golenbock D.T. The CD11/CD18 integrins: characterization of three novel LPS signaling receptors. Prog. Clin. Biol. Res. 1998, 397:107-117.
232. Ross G.D. Role of the lectin domain of Mac-1/CR3 (CD11b/CD18) in regulating intercellular adhesion. Immunol. Res. 2002, 25:219-227.
233. Xie J., Li R., Kotovuori P., Vermot-Desroches C., Wijdenes J., Arnaout M.A., Nortamo P., Gahmberg C.G. Intercellular adhesion molecule-2 (CD102) binds to the leukocyte integrin CD11b/CD18 through the A domain. J. Immunol. 1995, 155:3619-3628.
234. Ihanus E., Uotila L., Toivanen A., Stefanidakis M., Bailly P., Cartron J.P., Gahmberg C.G. Characterization of ICAM-4 binding to the I domains of the CD11a/CD18 and CD11b/CD18 leukocyte integrins. Eur. J. Biochem. 2003, 270:1710-1723.
235. Walzog B., Schuppan D., Heimpel C., Hafezi-Moghadam A., Gaehtgens P., Ley K. The leukocyte integrin Mac-1 (CD11b/CD18) contributes to binding of human granulocytes to collagen. Exp. Cell Res. 1995, 218:28-38.
236. Lishko V.K., Yakubenko V.P., Ugarova T.P. The interplay between integrins alphaMbeta2 and alpha5beta1 during cell migration to fibronectin. Exp. Cell Res. 2003, 283:116-126.
237. Santoso S., Sachs U.J., Kroll H., Linder M., Ruf A., Preissner K.T., Chavakis T. The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J. Exp. Med. 2002, 196:679-691.
238. Gustafson E.J., Lukasiewicz H., Wachtfogel Y.T., Norton K.J., Schmaier A.H., Niewiarowski S., Colman R.W. High molecular weight kininogen inhibits fibrinogen binding to cytoadhesins of neutrophils and platelets. J. Cell Biol. 1989, 109:377-387.
239. Choi J., Leyton L., Nham S.U. Characterization of alphaX I-domain binding to Thy-1. Biochem. Biophys. Res. Commun. 2005, 331:557-561.
240. Sadhu C., Ting H.J., Lipsky B., Hensley K., Garcia-Martinez L.F., Simon S.I., Staunton D.E. CD11c/CD18: novel ligands and a role in delayed-type hypersensitivity. J. Leukoc. Biol. 2007, 81:1395-1403.
241. Ihanus E., Uotila L.M., Toivanen A., Varis M., Gahmberg C.G. Red-cell ICAM-4 is a ligand for the monocyte/macrophage integrin CD11c/CD18: characterization of the binding sites on ICAM-4. Blood 2007, 109:802-810.
242. Garnotel R., Rittie L., Poitevin S., Monboisse J.C., Nguyen P., Potron G., Maquart F.X., Randoux A., Gillery P. Human blood monocytes interact with type I collagen through alpha x beta 2 integrin (CD11c-CD18, gp150-95). J. Immunol. 2000, 164:5928-5934.
243. Kikuchi M., Tachimoto H., Nutku E., Hudson S.A., Bochner B.S. Phorbol esters alter alpha4 and alphad integrin usage during eosinophil adhesion to VCAM-1. Cell Commun. Adhes. 2003, 10:119-128.
244. Van der Vieren M., Le Trong H., Wood C.L., Moore P.F., St John T., Staunton D.E., Gallatin W.M. A novel leukointegrin, alpha d beta 2, binds preferentially to ICAM-3. Immunity 1995, 3:683-690.
245. Ostermann G., Weber K.S., Zernecke A., Schroder A., Weber C. JAM-1 is a ligand of the beta(2) integrin LFA-1 involved in transendothelial migration of leukocytes. Nat. Immunol. 2002, 3:151-158.
246. Howe H.S., Kong K.O., Thong B.Y., Law W.G., Chia F.L., Lian T.Y., Lau T.C., Chng H.H., Leung B.P. Urine sVCAM-1 and sICAM-1 levels are elevated in lupus nephritis. Int. J. Rheum. Dis. 2012, 15:13-16.
247. Diacovo T.G., deFougerolles A.R., Bainton D.F., Springer T.A. A functional integrin ligand on the surface of platelets: intercellular adhesion molecule-2. J. Clin. Invest. 1994, 94:1243-1251.
248. Qi B.T., Wang P., Li J., Ren H.X., Xie M. Levels of soluble vascular cell adhesion molecule-1 and soluble intercellular adhesion molecule-2 in plasma of patients with hemorrhagic fever with renal syndrome, and significance of the changes in level. Viral Immunol. 2006, 19:565-569.
249. de Fougerolles A.R., Springer T.A. Intercellular adhesion molecule 3, a third adhesion counter-receptor for lymphocyte function-associated molecule 1 on resting lymphocytes. J. Exp. Med. 1992, 175:185-190.
250. Pino-Otin M.R., Vinas O., de la Fuente M.A., Juan M., Font J., Torradeflot M., Pallares L., Lozano F., Alberola-Ila J., Martorell J., et al. Existence of a soluble form of CD50 (intercellular adhesion molecule-3) produced upon human lymphocyte activation. Present in normal human serum and levels are increased in the serum of systemic lupus erythematosus patients. J. Immunol. 1995, 154:3015-3024.
251. Lindsberg P.J., Launes J., Tian L., Valimaa H., Subramanian V., Siren J., Hokkanen L., Hyypia T., Carpen O., Gahmberg C.G. Release of soluble ICAM-5, a neuronal adhesion molecule, in acute encephalitis. Neurology 2002, 58:446-451.
252. Leca G., Mansur S.E., Bensussan A. Expression of VCAM-1 (CD106) by a subset of TCR gamma delta-bearing lymphocyte clones. Involvement of a metalloprotease in the specific hydrolytic release of the soluble isoform. J. Immunol. 1995, 154:1069-1077.
253. Xie M., Chen P., He L.J., Qi B.T., Wang P., Wang X.F., Ren H.X. The detection of sLFA-3 in plasma of patients with hemorrhagic fever with renal syndrome. Clin. Exp. Med. 2009, 9:67-71.
254. Bevilacqua M.P., Stengelin S., Gimbrone M.A., Seed B. Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 1989, 243:1160-1165.
255. Siegelman M.H., Weissman I.L. Human homologue of mouse lymph node homing receptor: evolutionary conservation at tandem cell interaction domains. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:5562-5566.
256. Johnston G.I., Cook R.G., McEver R.P. Cloning of GMP-140, a granule membrane protein of platelets and endothelium: sequence similarity to proteins involved in cell adhesion and inflammation. Cell 1989, 56:1033-1044.